Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment

Journal of Allergy and Clinical Immunology

Volumn 124, Issue 6, 2009, Pages 1259-1266

  Brennan, Patrick J ^a   Bouza, Tito Rodriguez ^a   Hsu, F Ida ^a   Sloane, David E ^a   Castells, Mariana C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

adverse drug reaction; Allergy; anaphylaxis; drug allergy; hypersensitivity reaction; infliximab; monoclonal antibody; rapid desensitization; rituximab; trastuzumab

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; DIPHENHYDRAMINE; FAMOTIDINE; GLUCOCORTICOID; HYDROXYZINE; INFLIXIMAB; LORAZEPAM; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONTELUKAST; PARACETAMOL; RANITIDINE; RITUXIMAB; SALBUTAMOL; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALGORITHM; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; BREAST CANCER; CARDIOVASCULAR SYMPTOM; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DESENSITIZATION; DIARRHEA; DISEASE SEVERITY; DYSPNEA; ENTERITIS; FEMALE; FEVER; FLUSHING; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; JUVENILE RHEUMATOID ARTHRITIS; MALE; MEDICAL RECORD REVIEW; MUSCLE DISEASE; NAUSEA; NECK PAIN; NEUROLOGICAL COMPLICATION; NONHODGKIN LYMPHOMA; PARESTHESIA; PERTHES DISEASE; POLYMYOSITIS; PRESYNCOPE; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; SKIN TEST; STANDARDIZATION; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; THROAT TIGHTNESS; URTICARIA; VISUAL DISORDER; VOMITING; WEAKNESS; WHEEZING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN TESTS;

EID: 71349084892     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.009     Document Type: Article

References (51)

1. Ehrlich P. On Immunity with special reference to cell life. Proc R Society 66 (1899) 424-433
2. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
3. Albrecht H., Radosevich J.A., and Babich M. Fundamentals of antibody-related therapy and diagnostics. Drugs Today (Barc) 45 (2009) 199-211
4. Calogiuri G., Ventura M.T., Mason L., Valacca A., Buquicchio R., Cassano N., et al. Hypersensitivity reactions to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 14 (2008) 2883-2891
5. Dillman R.O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18 (1999) 465-471
6. Grillo-Lopez A.J., White C.A., Varns C., Shen D., Wei A., McClure A., et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26 (1999) 66-73
7. Baert F., Noman M., Vermeire S., Van Assche G., G D.H., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
8. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
9. Soykan I., Ertan C., and Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 95 (2000) 2395-2396
10. Herceptin prescribing information. Genentech; Revised 3/2009. Available at:http://www.gene.com/gene/products/information/pdf/herceptin-prescribi ng.pdf. Accessed July 1, 2009
11. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61 suppl 2 (2001) 58-66
12. Dreyfus D.H., and Randolph C.C. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 96 (2006) 624-627
13. Price K.S., and Hamilton R.G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28 (2007) 313-319
14. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
15. Baudouin V., Crusiaux A., Haddad E., Schandene L., Goldman M., Loirat C., et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 76 (2003) 459-463
16. Leonard P.A., Woodside K.J., Gugliuzza K.K., Sur S., and Daller J.A. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation 74 (2002) 1697-1700
17. Hawkins C., Gatenby P., and McGill D. Severe hypotension complicating primary angioplasty: allergy to abciximab. Allergy 58 (2003) 688-689
18. Pharand C., Palisaitis D.A., and Hamel D. Potential anaphylactic shock with abciximab readministration. Pharmacotherapy 22 (2002) 380-383
19. O'Neil B.H., Allen R., Spigel D.R., Stinchcombe T.E., Moore D.T., Berlin J.D., et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25 (2007) 3644-3648
20. Gell P.G.H., and Coombs R.R.A. Clinical Aspects of Immunology. 1st ed (1963), Blackwell, Oxford (UK)
21. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 6 (2006) 476-481
22. Morales A.R., Shah N., and Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 94 (2005) 575-580
23. Pruzansky J.J., and Patterson R. Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. Immunology 65 (1988) 443-447
24. Paolini R., Numerof R., and Kinet J.P. Phosphorylation/dephosphorylation of high-affinity IgE receptors: a mechanism for coupling/uncoupling a large signaling complex. Proc Natl Acad Sci U S A 89 (1992) 10733-10737
25. Rubinchik E., Shalit M., and Levi-Schaffer F. Responsiveness of human skin mast cells to repeated activation: an in vitro study. Allergy 53 (1998) 14-19
26. Macglashan D., and Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol 114 (2004) 1317-1324
27. Castells M.C., Tennant N.M., Sloane D.E., Hsu F.I., Barrett N.A., Hong D.I., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122 (2008) 574-580
28. Duburque C., Lelong J., Iacob R., Seddik M., Desreumaux P., Fournier C., et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 24 (2006) 851-858
29. Lelong J., Duburque C., Fournier C., Colombel J.F., Desreumaux P., Tonnel A.B., et al. Desensitisation to infliximab in patients with Crohn's disease. Rev Mal Respir 22 (2005) 239-246
30. Puchner T.C., Kugathasan S., Kelly K.J., and Binion D.G. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 7 (2001) 34-37
31. Lee C.W., Matulonis U.A., and Castells M.C. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99 (2005) 393-399
32. Melamed J., and Stahlman J.E. Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol 110 (2002) 813-814
33. Georgitis J.W., Browning M.C., Steiner D., and Lorentz W.B. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 66 (1991) 343-347
34. Jerath M.R., Kwan M., Kannarkat M., Mirakhur B., Carey L., Valgus J., et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 123 (2009) 260-262
35. Brown S.G. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114 (2004) 371-376
36. Feldweg A.M., Lee C.W., Matulonis U.A., and Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96 (2005) 824-829
37. Breslow R.G., Caiado J., and Castells M.C. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 102 (2009) 155-160
38. Chatenoud L., Baudrihaye M.F., Chkoff N., Kreis H., Goldstein G., and Bach J.F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137 (1986) 830-838
39. Frodin J.E., Lefvert A.K., and Mellstedt H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 21 (1992) 153-165
40. Legouffe E., Liautard J., Gaillard J.P., Rossi J.F., Wijdenes J., Bataille R., et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 98 (1994) 323-329
41. Curtis B.R., Swyers J., Divgi A., McFarland J.G., and Aster R.H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99 (2002) 2054-2059
42. Byrd J.C., Waselenko J.K., Maneatis T.J., Murphy T., Ward F.T., Monahan B.P., et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17 (1999) 791-795
43. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 26 (2006) 465-485
44. Bush R.K., Wood R.A., and Eggleston P.A. Laboratory animal allergy. J Allergy Clin Immunol 102 (1998) 99-112
45. Matsui E.C., Simons E., Rand C., Butz A., Buckley T.J., Breysse P., et al. Airborne mouse allergen in the homes of inner-city children with asthma. J Allergy Clin Immunol 115 (2005) 358-363
46. Matsui E.C., Wood R.A., Rand C., Kanchanaraksa S., Swartz L., and Eggleston P.A. Mouse allergen exposure and mouse skin test sensitivity in suburban, middle-class children with asthma. J Allergy Clin Immunol 113 (2004) 910-915
47. Park A., Edwards M., Donaldson M., Ghatei M., and Meeran K. Lesson of the week: interfering antibodies affecting immunoassays in woman with pet rabbits. BMJ 326 (2003) 541-542
48. Platts-Mills T.A., Satinover S.M., Naccara L., Litonjua A.A., Phipatanakul W., Carter M.C., et al. Prevalence and titer of IgE antibodies to mouse allergens. J Allergy Clin Immunol 120 (2007) 1058-1064
49. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 (2008) 1109-1117
50. Zanotti K.M., Rybicki L.A., Kennedy A.W., Belinson J.L., Webster K.D., Kulp B., et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19 (2001) 3126-3129
51. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66 (2007) 921-926